MX2013001279A - Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. - Google Patents
Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.Info
- Publication number
- MX2013001279A MX2013001279A MX2013001279A MX2013001279A MX2013001279A MX 2013001279 A MX2013001279 A MX 2013001279A MX 2013001279 A MX2013001279 A MX 2013001279A MX 2013001279 A MX2013001279 A MX 2013001279A MX 2013001279 A MX2013001279 A MX 2013001279A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- phosphodiesterase inhibitor
- selective enzyme
- gel form
- enzyme phosphodiesterase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Abstract
La presente invención se refiere a una novedosa composición farmacéutica para administración oral en forma de líquido y/o semisólido de liberación modificada que contiene una cantidad efectiva terapéuticamente de al menos un agente inhibidor selectivo de la enzima fosfodiesterasa y/o sus sales farmacéuticamente aceptables, en combinación con uno o más solventes y/o co-solventes y/o uno más excipientes farmacéuticamente aceptables. Mediante la novedosa composición desarrollada en la presente invención, se alcanzan concentraciones plasmáticas máximas por mayor tiempo, es decir, la liberación y absorción de sildenafil mediante la administración de la novedosa composición se lleva a cabo de manera sostenida con una absorción de forma paulatina.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013001279A MX2013001279A (es) | 2013-01-31 | 2013-01-31 | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. |
PCT/MX2014/000028 WO2014119985A2 (es) | 2013-01-31 | 2014-01-28 | Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013001279A MX2013001279A (es) | 2013-01-31 | 2013-01-31 | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013001279A true MX2013001279A (es) | 2013-08-26 |
Family
ID=49552933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013001279A MX2013001279A (es) | 2013-01-31 | 2013-01-31 | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. |
Country Status (2)
Country | Link |
---|---|
MX (1) | MX2013001279A (es) |
WO (1) | WO2014119985A2 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2584248A1 (es) * | 2015-03-24 | 2016-09-26 | Farmalider, S.A. | Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2649834C1 (ru) * | 2016-07-06 | 2018-04-04 | Фармалидер С.А. | Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения |
CN112587476B (zh) * | 2020-12-23 | 2022-09-27 | 无锡市妇幼保健院 | 一种适用于新生儿动脉高压的西地那非啫喱新剂型及其制备方法 |
CN113577079B (zh) * | 2021-07-28 | 2022-08-23 | 山东裕欣药业有限公司 | 一种磷酸二酯酶抑制剂的制备方法及组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060353A1 (fr) * | 2000-02-21 | 2001-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Preparation liquide a absorbabilite amelioree |
JP5686978B2 (ja) * | 2009-03-18 | 2015-03-18 | 第一三共ヘルスケア株式会社 | シルデナフィルクエン酸塩含有内服液剤及びその液剤含有容器 |
DE102009033396A1 (de) * | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
CN102204917B (zh) * | 2011-03-30 | 2013-10-09 | 天津红日药业股份有限公司 | 一种含有法舒地尔与西地那非的药物组合物及其制备方法和用途 |
-
2013
- 2013-01-31 MX MX2013001279A patent/MX2013001279A/es active IP Right Grant
-
2014
- 2014-01-28 WO PCT/MX2014/000028 patent/WO2014119985A2/es active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2584248A1 (es) * | 2015-03-24 | 2016-09-26 | Farmalider, S.A. | Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral |
Also Published As
Publication number | Publication date |
---|---|
WO2014119985A2 (es) | 2014-08-07 |
WO2014119985A3 (es) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
EA201692276A1 (ru) | Комбинации тиотропия бромида, формотерола и будесонида для лечения хобл | |
MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
CY1122598T1 (el) | Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης | |
CL2016002655A1 (es) | Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
MX352778B (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
EA201491870A1 (ru) | Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |